Join our Webinar
How CETSA® has been applied in Lead Generation delivering novel modulators of PLCγ2 4 December 2024 17:00 CET | 16:00 GMT | 11:00 EST | 08:00 PST Featured Speaker Fiona Jeganathan Head of Pharmac...
Meet us at BIO-Europe 2024
November 4-6, Stockholmsmässan | Stockholm – Sweden. Our CEO, Michael Dabrowski along with Regional Sales Manager Marianne Alksnis and Head of Sales Magnus Lejelöv, will be attending the Europe&...
Find us at 7th Annual TPD & Induced Proximity Summit
October 28-31, The Westin Copley Place | Boston – MA (US). We are attending the 7th TPD & Induced Proximity Summit, in Boston.Meet our Head of Sales North America, Brian Jarecki, and team at...
New privacy policy
We respect your integrity and ensure that your personal data is processed with the confidentiality and respect that is required. Therefore, We have revised our privacy policy.
We’re attending MSD Technology Symposium
Meet us on September 24-25, Greater Philadelphia Expo Center, Oaks, PA (US). New service Learn more about or latest contribution to our service portfolio; Standard Selectivity Profiling, by attending ...
Meet us at Discovery on Target
September 30 – October 3 we are attending the 22nd Discovery on Target conference, in Boston. Meet our Head of Sales North America, Brian Jarecki, and team. They will tell you all about how we c...
Pelago Bioscience AB signs strategic agreement with Cancer Research Horizons
Pelago Bioscience AB signs a strategic agreement with Cancer Research Horizons to unlock quantitative assessment of cellular target engagement across its pipeline of novel oncology programmes. The com...
BellBrook Labs acknowledges Pelago Bioscience’s patent and use of CETSA® process
In connection with the CETSA platform, the BellBrook Labs, LLC states: “BellBrook Labs wishes to acknowledge the validity of Pelago Biosciences patented and trademarked CETSA technology (US Pat. Nos. ...
University of Edinburgh acknowledges Pelago Bioscience’s patent and use of CETSA® process
In connection with the CETSA platform, the University of Edinburgh states: “The University of Edinburgh wishes to acknowledge the validity of Pelago’s CETSA patent (EP 2 699 910 B1) entitled “Methods ...
New CETSA® Publication
Quantitative target engagement of RIPK1 in human whole blood via the cellular thermal shift assay for potential pre-clinical and clinical applications In a recent collaboration between AbbVie Chemical...
Unlocking Proteomics: Pelago Bioscience’s HUPO Award-Winning CETSA® approach
Stockholm, Sweden 12 September 2023 Pelago Bioscience proudly receives the HUPO Science and Technology Award, celebrating our pioneering work in CETSA (Cellular Thermal Shift Assay) and the Pelago tea...
Pelago Bioscience Featured in Top Ten Most Popular Drug Hunter Resources of 2023
We’re delighted to share that our commitment to advancing Drug Discovery has earned us a spot in the “Top Ten Most Popular Drug Hunter Resources of 2023.” The insightful article, “Drug Target Identifi...
A Shift in Thinking: Cellular Thermal Shift Assay-Enabled Drug Discovery
We are thrilled to share our latest publication in the journal “ACS Medicinal Chemistry Letters” titled – A Shift in Thinking: Cellular Thermal Shift Assay-Enabled Drug Discovery. In this study, we hi...